| abstract |
Disclosed is a compound according to formula (I) wherein A1 is alkyl-NH-alkyl, alkylcarbonyl, alkylsulfonyl, cycloalkyl, cycloalkylcarbonyl, cycloalkylsulfonyl, arylcarbonyl, arylsulfonyl, heterocyclecarbonyl, heterocyclesulfonyl, arylalkyl, aryloxyalkyl, carboxyalkyl, carboxycycloalkyl, haloalkyl, heterocycle, heterocyclealkyl, heterocycleoxyalkyl, -NR7-[C(R8R9)]n-C(O)-R10, -O-[C(R11R12)]p-C(O)-R13, -N(R15R16), -CO2R17, -C(O)-N(R18R19), -CR20R21)-OR22, or -C(R23R24)-N(R25R26); and wherein the rest of the substituents are disclosed within the specification. Also disclosed is the use of a compound of formula (I) in the manufacture of a medicament for treating a disorder associated with the inhibition of 11-beta-hydroxysteroiddehydrogenase type 1 enzyme selected from Cushing's syndrome, non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, hypertension, atherosclerosis, glaucoma, and osteoporosis. |